A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple...

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• There is a critical need for advanced cancer therapies that prevent tumor progression and resistance.
• Targeting multiple receptor tyrosine kinases (RTKs) is a promising strategy for comprehensive cancer treatment.

Purpose of the Study:

• To develop and validate peptide-based vaccines and mimics targeting key RTKs involved in cancer.
• To identify effective combinations of peptide vaccines to inhibit multiple signaling pathways and overcome tumor resistance.

Main Methods:

• Creation of a validated portfolio of peptide epitopes against EGFR, HER-2, HER-3, VEGF, and IGF-1R.
• Design of chimeric conformational B-cell epitopes incorporating promiscuous T-cell epitopes for sustained immune responses.
• Development of peptide mimics acting as antagonists to RTK signaling.

Main Results:

• Identification of optimal combinations of peptide vaccines/mimics for selective inhibition of multiple RTKs.
• Demonstration of synergistic effects in combinatorial immunotherapeutic strategies.
• Generation of high-affinity anti-peptide antibodies with potential as vaccines.

Conclusions:

• Combinatorial immunotherapies using peptide vaccines targeting multiple RTKs offer a promising strategy to enhance anti-tumor immunity.
• This approach has the potential to address mechanisms of tumor resistance across various cancer types.
• The developed peptide vaccines and mimics can act as antagonists to signaling pathways driving cancer metastasis.